My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 572

    1.

    Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor.

    Aso Y, Wakabayashi S, Yamamoto R, Matsutomo R, Takebayashi K, Inukai T.

    Diabetes Care. 2005 Sep;28(9):2211-6.PMID: 16123492 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Plasminogen activator inhibitor-1 and thrombin activatable fibrinolysis inhibitor levels in non-alcoholic steatohepatitis.

    Yener S, Akarsu M, Demir T, Akinci B, Sagol O, Bayraktar F, Ozcan MA, Tankurt E, Yesil S.

    J Endocrinol Invest. 2007 Nov;30(10):810-9.PMID: 18075282 [PubMed - indexed for MEDLINE]Related articles

    3.

    Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes.

    Kahn SE, Zinman B, Haffner SM, O'Neill MC, Kravitz BG, Yu D, Freed MI, Herman WH, Holman RR, Jones NP, Lachin JM, Viberti GC; ADOPT Study Group.

    Diabetes. 2006 Aug;55(8):2357-64.PMID: 16873701 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients.

    Kitagawa N, Yano Y, Gabazza EC, Bruno NE, Araki R, Matsumoto K, Katsuki A, Hori Y, Nakatani K, Taguchi O, Sumida Y, Suzuki K, Adachi Y.

    Diabetes Res Clin Pract. 2006 Aug;73(2):150-7. Epub 2006 Feb 3.PMID: 16458385 [PubMed - indexed for MEDLINE]Related articles

    5.

    High serum high-sensitivity C-reactive protein concentrations are associated with relative cardiac sympathetic overactivity during the early morning period in type 2 diabetic patients with metabolic syndrome.

    Aso Y, Wakabayashi S, Nakano T, Yamamoto R, Takebayashi K, Inukai T.

    Metabolism. 2006 Aug;55(8):1014-21.PMID: 16839835 [PubMed - indexed for MEDLINE]Related articles

    6.

    Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.

    Yener S, Comlekci A, Akinci B, Demir T, Yuksel F, Ozcan MA, Bayraktar F, Yesil S.

    Med Princ Pract. 2009;18(4):266-71. Epub 2009 Jun 2.PMID: 19494532 [PubMed - indexed for MEDLINE]Related articles

    7.

    Plasma TAFI and soluble CD40 ligand do not predict reperfusion following thrombolysis for acute myocardial infarction.

    Cruden NL, Graham C, Harding SA, Ludlam CA, Fox KA, Newby DE.

    Thromb Res. 2006;118(2):189-97. Epub 2005 Aug 1.PMID: 16055173 [PubMed - indexed for MEDLINE]Related articles

    8.

    Enhancement of fibrinolysis in poorly controlled, hospitalized type 2 diabetic patients by short-term metabolic control: association with a decrease in plasminogen activator inhibitor 1.

    Aso Y, Okumura KI, Yoshida N, Tayama K, Takemura Y, Inukai T.

    Exp Clin Endocrinol Diabetes. 2004 Apr;112(4):175-80.PMID: 15127320 [PubMed - indexed for MEDLINE]Related articles

    9.

    Impaired fibrinolytic compensation for hypercoagulability in obese patients with type 2 diabetes: association with increased plasminogen activator inhibitor-1.

    Aso Y, Matsumoto S, Fujiwara Y, Tayama K, Inukai T, Takemura Y.

    Metabolism. 2002 Apr;51(4):471-6.PMID: 11912556 [PubMed - indexed for MEDLINE]Related articles

    10.

    Increased plasminogen activator inhibitor-1 activity in offspring of type 2 diabetic patients: lack of association with plasma insulin levels.

    Gürlek A, Bayraktar M, Kirazli S.

    Diabetes Care. 2000 Jan;23(1):88-92.PMID: 10857975 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Postprandial thrombin activatable fibrinolysis inhibitor and markers of endothelial dysfunction in type 2 diabetic patients.

    Rigla M, Wägner AM, Borrell M, Mateo J, Foncuberta J, de Leiva A, Ordóñez-Llanos J, Pérez A.

    Metabolism. 2006 Nov;55(11):1437-42.PMID: 17046544 [PubMed - indexed for MEDLINE]Related articles

    12.

    Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels.

    Erem C, Nuhoglu I, Yilmaz M, Kocak M, Demirel A, Ucuncu O, Onder Ersoz H.

    J Endocrinol Invest. 2009 Feb;32(2):169-74.PMID: 19411818 [PubMed - indexed for MEDLINE]Related articles

    13.

    Fibrinolytic parameters and insulin resistance in young survivors of myocardial infarction with heterozygous familial hypercholesterolemia.

    Sebestjen M, Zegura B, Guzic-Salobir B, Keber I.

    Wien Klin Wochenschr. 2001 Feb 15;113(3-4):113-8.PMID: 11253736 [PubMed - indexed for MEDLINE]Related articles

    14.

    Thrombin activatable fibrinolysis inhibitor antigen levels are inversely correlated with plasminogen activator inhibitor-1 antigen levels in hyperthyroid patients.

    Akinci B, Comlekci A, Yener S, Demir T, Ozcan MA, Bayraktar F, Yesil S.

    Endocr J. 2007 Aug;54(4):593-9. Epub 2007 Aug 10.PMID: 17690487 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    The metabolic syndrome is associated with elevated circulating C-reactive protein in healthy reference range, a systemic low-grade inflammatory state.

    Tamakoshi K, Yatsuya H, Kondo T, Hori Y, Ishikawa M, Zhang H, Murata C, Otsuka R, Zhu S, Toyoshima H.

    Int J Obes Relat Metab Disord. 2003 Apr;27(4):443-9.PMID: 12664077 [PubMed - indexed for MEDLINE]Related articles

    16.

    Insulin resistance is associated with increased circulating level of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients.

    Hori Y, Gabazza EC, Yano Y, Katsuki A, Suzuki K, Adachi Y, Sumida Y.

    J Clin Endocrinol Metab. 2002 Feb;87(2):660-5.PMID: 11836301 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    The relationship between plasminogen activator inhibitor-1 and insulin resistance in newly diagnosed type 2 diabetes mellitus.

    Gough SC, Rice PJ, McCormack L, Chapman C, Grant PJ.

    Diabet Med. 1993 Aug-Sep;10(7):638-42.PMID: 8403825 [PubMed - indexed for MEDLINE]Related articles

    18.

    Metalloproteinase-2 and -9 in diabetic and nondiabetic subjects during acute coronary syndromes.

    Derosa G, Cicero AF, Scalise F, Avanzini MA, Tinelli C, Piccinni MN, Peros E, Geroldi D, Fogari E, D'Angelo A.

    Endothelium. 2007 Jan-Feb;14(1):45-51.PMID: 17364896 [PubMed - indexed for MEDLINE]Related articles

    19.

    Non-alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in non-diabetic men. Role of visceral adipose tissue.

    Targher G, Bertolini L, Scala L, Zoppini G, Zenari L, Falezza G.

    Diabet Med. 2005 Oct;22(10):1354-8.PMID: 16176196 [PubMed - indexed for MEDLINE]Related articles

    20.

    Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism.

    Erem C, Kocak M, Nuhoglu I, Yilmaz M, Ucuncu O.

    Eur J Endocrinol. 2009 May;160(5):863-8. Epub 2009 Feb 20.PMID: 19233920 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity